Wellington Shields Capital Management LLC maintained its stake in Amgen, Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,375 shares of the medical research company’s stock at the end of the 2nd quarter. Wellington Shields Capital Management LLC’s holdings in Amgen were worth $409,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Camelot Portfolios LLC purchased a new position in Amgen during the first quarter worth about $1,429,000. PGGM Investments grew its position in Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after buying an additional 15,059 shares during the period. Shelton Capital Management grew its position in Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after buying an additional 49,354 shares during the period. Cadence Bank NA grew its position in Amgen by 6.2% during the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares during the period. Finally, Telos Capital Management Inc. grew its position in Amgen by 1.6% during the first quarter. Telos Capital Management Inc. now owns 14,348 shares of the medical research company’s stock worth $2,354,000 after buying an additional 227 shares during the period. 78.14% of the stock is owned by institutional investors and hedge funds.
Amgen, Inc. (AMGN) traded down 0.98% during trading on Friday, reaching $187.59. 3,240,437 shares of the company traded hands. The company has a market cap of $136.88 billion, a PE ratio of 17.09 and a beta of 1.35. Amgen, Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The company’s 50-day moving average is $174.87 and its 200 day moving average is $169.24.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 27.67% and a net margin of 37.02%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 EPS. On average, analysts anticipate that Amgen, Inc. will post $12.57 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.43%. Amgen’s payout ratio is 41.93%.
ILLEGAL ACTIVITY NOTICE: “Wellington Shields Capital Management LLC Has $409,000 Stake in Amgen, Inc. (AMGN)” was first published by BBNS and is owned by of BBNS. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/wellington-shields-capital-management-llc-continues-to-hold-stake-in-amgen-inc-amgn/1605320.html.
A number of analysts recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday. They set a “sector perform” rating and a $192.00 target price on the stock. Cann reaffirmed a “buy” rating and set a $203.00 price target (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 26th. Deutsche Bank AG reissued a “hold” rating and issued a $174.00 target price (up previously from $172.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $186.14.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.